How Diabetes and High Cholesterol Shape Brain Pathology in Alzheimer Disease

Alzheimer disease rarely travels alone. Cardiovascular risk factors — diabetes, hypertension, and high cholesterol — are well-established contributors to cognitive decline, but precisely how they shape the regional distribution of Alzheimer neuropathology once advanced disease is present has been poorly understood. This autopsy-based cohort study set out to fill that gap.

The researchers enrolled 276 deceased individuals with pathologically confirmed intermediate or high Alzheimer disease drawn from three Alzheimer's Disease Research Centers. Brain tissue was scored semi-quantitatively for seven neuropathological features across multiple regions: arteriolosclerosis, cerebral amyloid angiopathy (CAA), cored plaques, diffuse plaques, neurofibrillary tangles, neuritic plaques, and neuropil threads. Cardiovascular risk factor status — diabetes, hypertension, or hypercholesterolemia, each treated as present or absent — was correlated with these scores using Wilcoxon rank-sum tests and ordinal logistic regression adjusted for ethnicity, sex, age at death, and study center.

Before correcting for multiple comparisons, two associations emerged. Diabetes was associated with a roughly threefold higher odds of greater neuropil thread burden in the frontal lobe (OR 3.2, 95% CI 1.2–8.4). Hypercholesterolemia was associated with approximately 2.7- to 2.8-fold higher odds of greater CAA severity in the parietal lobe and posterior hippocampus. These are biologically plausible signals — vascular and metabolic dysfunction could plausibly accelerate amyloid deposition in vessel walls and tau-related axonal damage.

However, none of these associations survived false discovery rate correction. The authors conclude that, in a cohort already burdened with advanced Alzheimer pathology, cardiovascular risk factors do not substantially amplify regional neuropathology — their independent effects, if any, are likely modest at this disease stage.

For clinicians and longevity-focused readers, the implication is cautionary: vascular risk management may matter most earlier in the disease course, before advanced pathology has accumulated. Intervening on diabetes and cholesterol as primary prevention — rather than expecting measurable neuropathological benefit once Alzheimer is established — remains the more defensible strategy.